Home > Dermatology > Unresolved needs for patients with PsA despite growing therapeutic options

Unresolved needs for patients with PsA despite growing therapeutic options

Conference
WPPAC 2021
The multinational 2020 UPLIFT survey of patients with psoriatic arthritis (PsA) saw a greater proportion of patients receiving systemic treatment compared with the 2012 MAPP survey, and yet three-quarters of patients in UPLIFT considered their disease moderate-to-severe. On top of that, only half of patients reported seeing a healthcare provider in the past year. Hence, there is an unmet need to better manage persistent disease [1].

Patients with PsA experience a high disease burden and a wide range of comorbidities that negatively impact their health-related quality of life [2]. The 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey assessed the impact of psoriasis and PsA on patients [3]. MAPP results revealed a high patient-reported disease burden –measured by quality of life, work productivity, and treatment burden– and significant impact of PsA on physical function and the need for improved treatment.
2012 versus 2020

As the therapeutic landscape has evolved since the MAPP survey, the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey evaluated how patient perceptions and behaviours may have changed since MAPP and identified persisting areas of unmet need. UPLIFT was a multinational, online survey conducted from 2 March to 3 June 2020 in the USA, Canada, UK, France, Germany, Italy, Spain, and Japan. The MAPP survey was conducted in the same countries except for Japan. Both surveys included adults with healthcare provider-diagnosed psoriasis and/or PsA. Differences between the 2 populations included that the UPLIFT population was younger (mean age 43 vs 56 years), included more men (54% vs 40%), and was less obese (20% vs 36%) than the MAPP population [1].
Disease burden and treatment

Concerning disease burden, similar rates of dactylitis and joint involvement but higher rates of enthesitis were observed in patients with PsA in UPLIFT versus MAPP. Patients surveyed in UPLIFT had higher rates of comorbidities than patients in MAPP. The underlying reasons are not fully understood.

Considerably fewer untreated patients were observed in UPLIFT than in MAPP (17% vs 28%), but fewer patients reported seeing a healthcare provider in the past year in UPLIFT compared with MAPP. Although 78% of UPLIFT patients were receiving some form of PsA treatment, 74% characterised their PsA as moderate or severe versus 88% in MAPP [1].
Unmet need remains

Although a greater proportion of patients in the 2020 UPLIFT survey received current treatment compared with the 2012 MAPP survey, approximately three-quarters of patients in UPLIFT considered their disease moderate-to-severe. In addition, only half of patients reported seeing a healthcare provider in the past year. These results suggest that, although the number of available treatment options has increased since MAPP, an unmet need for PsA patient care remains [1].

  1. Ogdie A. Changes in Patient Perceptions of Psoriatic Arthritis From 2012 to 2020: Results From the UPLIFT Survey. Abstract O5, 6th World Psoriasis & Psoriatic Arthritis Conference, 30 June–3 July 2021.
  2. Gladman DD, et al. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii14–7.
  3. Kavanaugh A, et al. Rheumatol Ther. 2016;3:91–102.

 

Copyright ©2021 Medicom Medical Publishers



Posted on